INOVIO PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inovio Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Inovio Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$25.2M, a 25.8% increase year-over-year.
  • Inovio Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$113M, a 31.4% increase year-over-year.
  • Inovio Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$135M, a 51.7% increase from 2022.
  • Inovio Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$280M, a 7.85% increase from 2021.
  • Inovio Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$304M, a 82.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$113M -$25.2M +$8.76M +25.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$122M -$32.2M +$3.3M +9.28% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$125M -$30.5M +$10.2M +25% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$135M -$25M +$29.5M +54.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$165M -$33.9M +$3.85M +10.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$168M -$35.5M +$73M +67.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$241M -$40.6M +$38.4M +48.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$280M -$54.5M +$52.5M +49.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$332M -$37.8M +$22.4M +37.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$355M -$108M -$26.4M -32.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$328M -$79.1M -$24.7M -45.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$304M -$107M -$82.6M -339% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 -$221M -$60.2M -$79.3M -414% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$142M -$82.1M +$46.6M +36.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$188M -$54.4M -$21.9M -67.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$166M -$24.3M +$13.3M +35.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$180M $19.2M +$42.3M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$222M -$129M -$99.3M -338% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$123M -$32.5M -$3.32M -11.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$119M -$37.7M -$4.7M -14.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$115M -$23.1M +$1.92M +7.7% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$117M -$29.4M -$22.7M -343% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$93.8M -$29.2M +$3.13M +9.68% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$97M -$33M -$11.5M -53.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$85.5M -$25M +$9.12M +26.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$94.6M -$6.64M +$2.84M +30% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$97.5M -$32.4M -$9.26M -40.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$88.2M -$21.5M +$4.73M +18% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-14
Q3 2017 -$92.9M -$34.1M -$13.4M -64.4% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$79.6M -$9.48M +$9.23M +49.3% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$88.8M -$23.1M -$15M -187% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$73.7M -$26.2M -$8.28M -46.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-14
Q3 2016 -$65.5M -$20.8M -$26.4M -471% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-14
Q2 2016 -$39.1M -$18.7M -$12.5M -199% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-14
Q1 2016 -$26.6M -$8.04M +$2.54M +24% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-14
Q4 2015 -$29.2M -$18M -$10.5M -142% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-15
Q3 2015 -$18.6M $5.59M +$12.8M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-15
Q2 2015 -$31.4M -$6.25M +$4.46M +41.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-15
Q1 2015 -$35.9M -$10.6M +$240K +2.22% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-15
Q4 2014 -$36.1M -$7.41M +$8.04M +52% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-14
Q3 2014 -$44.2M -$7.18M +$23.7M +76.8% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-14
Q2 2014 -$67.9M -$10.7M +$141K +1.3% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-14
Q1 2014 -$68M -$10.8M -$1.98M -22.4% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-14
Q4 2013 -$66M -$15.5M -$14.8M -2246% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-16
Q3 2013 -$51.2M -$30.9M -$24.3M -366% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-16
Q2 2013 -$27M -$10.9M -$6.72M -163% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-16
Q1 2013 -$20.3M -$8.84M -$589K -7.14% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-16
Q4 2012 -$19.7M -$659K +$4.82M +88% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-17
Q3 2012 -$24.5M -$6.62M -$2.08M -45.8% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-17
Q2 2012 -$22.4M -$4.13M -$1.31M -46.5% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-17
Q1 2012 -$21.1M -$8.25M -$5.84M -242% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-17
Q4 2011 -$15.3M -$5.48M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-18
Q3 2011 -$4.54M -$3.13M -222% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-18
Q2 2011 -$2.82M +$4.79M +62.9% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-18
Q1 2011 -$2.41M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-18
Q3 2010 -$1.41M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 -$7.62M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.